Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
We have a wide range of fun and festive designs to choose from. Fund life changing research while spreading joy this Christmas!
This Christmas, your gift can bring us closer to a cure for type 1 diabetes – and every pound you give to our Christmas Appeal will be doubled.
The announcement is the biggest treatment breakthrough for type 1 diabetes since the discovery of insulin.
This event is designed for anyone living with type 1 diabetes who would like to learn more about managing their wellbeing across a variety of contexts.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
Home > About JDRF & our impact > Our research > Cure research > Immune therapies > FAQs about teplizumab
Teplizumab is an immunotherapy drug, which has just been approved by the USA’s Food and Drug Administration (FDA) to delay type 1 diabetes. It helps to protect the insulin-producing beta cells from the immune attack that causes type 1 by attaching to markers on a type of immune cell called T-cells. Teplizumab has been shown to delay the development of type 1 in at-risk individuals by an average of three years.
Teplizumab is the first disease-modifying therapy available to delay clinical type 1 in individuals at high risk anywhere in the world. The approval of teplizumab proves to funders of research in government and industry that it is possible to develop drugs for type 1. This should lead to an increase in funding for type 1 diabetes research and hopefully bring about more treatments.
A delay in clinical type 1 diabetes of at least two years is clinically meaningful. Any time period that a person does not have to be dependent on insulin means they are avoiding important risks such as hypoglycemia and the significant constant burdens of life with type 1. This can also play a key role in preventing complications such as eye, kidney, and heart diseases.
The FDA is the largest global medical licensing agency, so often drug manufacturers apply to the FDA first to approve their new drug. If the FDA approves a drug, it is likely that the MHRA (who approve drugs in the UK) and the EMA (who approve drugs in Europe) will do so too. Both the MHRA and the EMA have granted teplizumab procedures to fast-track them through the approval process.
The approval agencies just address the safety of the drug. For teplizumab to be adopted in the UK, NICE must deem it clinically cost effective and adopt it under the NHS. There is lots of positive evidence for this, but the logistics of clinical delivery must also be worked out. An education programme for doctors needs to be developed to teach them how to manage people who aren’t yet diagnosed with type 1. Dr Rachel Besser is working on this – read her blog post.
There are trial screening programmes in the UK that test children’s blood for markers of the very early stages of type 1. One of these is called the ELSA study and screens children aged 3-13 years across the UK. Every child between that age bracket is eligible to be screened.
Researchers are also testing teplizumab in people recently diagnosed with type 1 via the PROTECT study. The study was possible thanks to the JDRF co-funded UK T1D Research Consortium, which recruits people with type 1 into UK clinical trials of new immunotherapy treatments. Recruitment for this study has now closed, but you can use our clinical trials finder to see which other studies you are eligible for.
In the clinical trial under review, some people who took teplizumab developed a rash and had a temporary lower level of white blood cells than they should have. White blood cells are cells within the immune system that help fight off infectious diseases. Crucially, the participants’ white blood cell count soon returned to normal.
Other drugs that target the immune system – known as immunotherapy drugs – are being developed and tested on people with type 1. An example of this is ustekinumab, a drug licensed to treat other autoimmune conditions including psoriasis, which is being trialed in children recently diagnosed with type 1. The approval of teplizumab sets a precedent that immunotherapies are a viable treatment for type 1. This encourages pharmaceutical companies to invest in them and paves the way for more drugs to become available.
As part of our mission to accelerate life-changing breakthroughs, JDRF played a key role in funding early-stage research and facilitating regulatory pathways to help bring teplizumab to market. As well as co-funding the UK T1D Research Consortium, JDRF has funded international clinical networks that supported early clinical trials to determine who would benefit from teplizumab and whether the drug works for people both with and at high risk of type 1.
We have continuously funded a researcher called Professor Kevan Herold, who initially showed that an immunotherapy drug could prevent type 1 in mice. This drug later became a version that could be used in humans: teplizumab. Professor Herold was the lead on the first ever study to effectively delay the onset of type 1, which formed the basis of the FDA approval application. He is still receiving JDRF funding to explore the biological mechanisms through which teplizumab delays type 1 development.
Drugs that target our immune system are called immune therapies or immunotherapies. Learn about the immunotherapy research we're funding.
Learn about how we're partnering with other autoimmune research funders to investigate how immune disorders are linked. Together, we aim to prevent and cure a range of autoimmune conditions including type 1 diabetes.
Treating type 1 means helping people achieve better glucose control, with less effort. It also means looking for ways to prevent or cure the complications that can develop from living with type 1. Discover our latest projects.
It’s thanks to your dedication that we have funded great progress in type 1 cure, treatment and prevention research. Help us to continue our vital research.